Analysis enhancement is defined as a perceived improvement of a person's overall ability to logically process information or creatively analyze concepts, ideas, and scenarios. This effect can lead to a deep state of contemplation which often results in an abundance of new and insightful ideas. It can give the person a perceived ability to better analyze concepts and problems in a manner which allows them to reach new conclusions, perspectives, and solutions which would have been otherwise difficult to conceive of.
Although this effect will often result in deep states of introspection, in other cases it can produce states which are not introspective but instead result in a deep analysis of the exterior world, both taken as a whole and as the things which comprise it. This can result in a perceived abundance of insightful ideas and conclusions with powerful themes pertaining to what is often described as "the bigger picture". These ideas generally involve (but are not limited to) insight into philosophy, science, spirituality, society, culture, universal progress, humanity, loved ones, the finite nature of our lives, history, the present moment, and future possibilities.
Cognitive performance is undeniably linked to personality, and it has been repeatedly shown that psychedelics alter a user's personality for the long term. Experienced psychedelics users score significantly better than controls on several psychometric measures.
Analysis enhancement is often accompanied by other coinciding effects such as stimulation, personal bias suppression, conceptual thinking, and thought connectivity. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds, such as amphetamine, methylphenidate, nicotine, and caffeine. However, it can also occur in a more powerful although less consistent form under the influence of psychedelics such as certain LSD, psilocybin, and mescaline.
Compounds within our psychoactive substance index which may cause this effect include:
Anecdotal reports which describe this effect within our experience index include:
- Experience:1000 Morning Glory seeds - Rediscovering the Self
- Experience:120µg LSD - First Bad Acid Trip, Psychosis
- Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
- Experience:20mg - I looked up and saw an angry god-like figure made of clouds glaring down at me
- Experience:225ug - Sheer Awe and Joy
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:300µg LSD - Togetherness and the Silent Dusk
- Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
- Experience:800ug LSD - 3D Vision
- Experience:LSD (~500μg, sublingual) + Noopept - Mind Reset
- Fillmore, Mark T.; Kelly, Thomas H.; Martin, Catherine A. (2005). "Effects of d-amphetamine in human models of information processing and inhibitory control". Drug and Alcohol Dependence. 77 (2): 151–159. doi:10.1016/j.drugalcdep.2004.07.013. ISSN 0376-8716.
- Bättig, K.; Buzzi, R. (1986). "Effect of Coffee on the Speed of Subject-Paced Information Processing". Neuropsychobiology. 16 (2-3): 126–130. doi:10.1159/000118312. ISSN 0302-282X.
- Warburton, David; Bersellini, Elisabetta; Sweeney, Eve (2001). "An evaluation of a caffeinated taurine drink on mood, memory and information processing in healthy volunteers without caffeine abstinence". Psychopharmacology. 158 (3): 322–328. doi:10.1007/s002130100884. ISSN 0033-3158.
- Humphreys, Michael S.; Revelle, William (1984). "Personality, motivation, and performance: A theory of the relationship between individual differences and information processing". Psychological Review. 91 (2): 153–184. doi:10.1037/0033-295X.91.2.153. ISSN 1939-1471.
- Bouso, José Carlos; Palhano-Fontes, Fernanda; Rodríguez-Fornells, Antoni; Ribeiro, Sidarta; Sanches, Rafael; Crippa, José Alexandre S.; Hallak, Jaime E.C.; de Araujo, Draulio B.; Riba, Jordi (2015). "Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans". European Neuropsychopharmacology. 25 (4): 483–492. doi:10.1016/j.euroneuro.2015.01.008. ISSN 0924-977X.